Skip to main content

Roche buys Wisconsin gene therapy company


Roche will buy a Wisconsin gene therapy company developing a mechanism to turn off genes associated with cancer and other diseases, Roche announced Tuesday.

In a deal worth $125 million, Roche will buy Mirus Bio. The Madison, Wisc., company is developing a technology called RNAi, also known as gene silencing. Roche plans to keep the development of the technology in Madison.

Another company developing gene silencing, Alnylam Pharmaceuticals, sold its rights to the technology to Roche last year, and the Swiss company had made an offer earlier this week for Genentech.

This ad will auto-close in 10 seconds